Tags

Type your tag names separated by a space and hit enter

Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis.
Mol Cell Biochem. 2004 Apr; 259(1-2):217-22.MC

Abstract

Excess amount of cytokine produced by inflammatory stimuli contributes to the progression of myocardial damage in myocarditis. Some angiotensin II receptor type 1 antagonists are reported to inhibit proinflammatory cytokine production in vitro and in vivo. We tested the hypothesis that olmesartan, a novel angiotensin II receptor type 1 antagonist, ameliorated experimental autoimmune myocarditis (EAM) in rats attributing to the suppression of inflammatory cytokines in the heart. We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The results showed that olmesartan decreased blood pressure significantly compared with the untreated group, but markedly reduced the severity of myocarditis by comparing the heart weight/body weight ratio, pericardial effusion scores, macroscopic scores and microscopic scores. Myocardial interleukin (IL)- 1beta expression by western blotting and IL-1beta-positive staining cells by immunohistochemistry were significantly lower in rats with EAM given olmesartan treatment compared with those of rats given vehicle. We conclude that Olmesartan ameliorates acute EAM in rats. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications.

Authors+Show Affiliations

Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15124927

Citation

Nimata, Masaomi, et al. "Beneficial Effects of Olmesartan, a Novel Angiotensin II Receptor Type 1 Antagonist, Upon Acute Autoimmune Myocarditis." Molecular and Cellular Biochemistry, vol. 259, no. 1-2, 2004, pp. 217-22.
Nimata M, Kishimoto C, Yuan Z, et al. Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis. Mol Cell Biochem. 2004;259(1-2):217-22.
Nimata, M., Kishimoto, C., Yuan, Z., & Shioji, K. (2004). Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis. Molecular and Cellular Biochemistry, 259(1-2), 217-22.
Nimata M, et al. Beneficial Effects of Olmesartan, a Novel Angiotensin II Receptor Type 1 Antagonist, Upon Acute Autoimmune Myocarditis. Mol Cell Biochem. 2004;259(1-2):217-22. PubMed PMID: 15124927.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis. AU - Nimata,Masaomi, AU - Kishimoto,Chiharu, AU - Yuan,Zuyi, AU - Shioji,Keisuke, PY - 2004/5/6/pubmed PY - 2005/1/26/medline PY - 2004/5/6/entrez SP - 217 EP - 22 JF - Molecular and cellular biochemistry JO - Mol Cell Biochem VL - 259 IS - 1-2 N2 - Excess amount of cytokine produced by inflammatory stimuli contributes to the progression of myocardial damage in myocarditis. Some angiotensin II receptor type 1 antagonists are reported to inhibit proinflammatory cytokine production in vitro and in vivo. We tested the hypothesis that olmesartan, a novel angiotensin II receptor type 1 antagonist, ameliorated experimental autoimmune myocarditis (EAM) in rats attributing to the suppression of inflammatory cytokines in the heart. We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The results showed that olmesartan decreased blood pressure significantly compared with the untreated group, but markedly reduced the severity of myocarditis by comparing the heart weight/body weight ratio, pericardial effusion scores, macroscopic scores and microscopic scores. Myocardial interleukin (IL)- 1beta expression by western blotting and IL-1beta-positive staining cells by immunohistochemistry were significantly lower in rats with EAM given olmesartan treatment compared with those of rats given vehicle. We conclude that Olmesartan ameliorates acute EAM in rats. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications. SN - 0300-8177 UR - https://www.unboundmedicine.com/medline/citation/15124927/Beneficial_effects_of_olmesartan_a_novel_angiotensin_II_receptor_type_1_antagonist_upon_acute_autoimmune_myocarditis_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=15124927.ui DB - PRIME DP - Unbound Medicine ER -